Clinical Intervention Protocols for Glucagon (2026)

Clinical Indications and Diagnostic Thresholds for Glucagon Administration

According to the 2026 clinical intervention protocols for primary care paramedics, the administration of glucagon is indicated in the presence of hypoglycemia, defined as a blood glucose level strictly lower than $4\,mmol/L$. Beyond this numerical threshold, the patient must exhibit specific clinical conditions that prevent the effective use of oral glucose. These conditions include an complete inability to ingest a glucose solution orally ($PO$) or the persistence of hypoglycemic symptoms and a low glucose reading at least $15\,\text{minutes}$ after the delivery of a second dose of an oral glucose solution.

Contraindications and Available Product Presentations

The primary contraindication for the use of specifically branded GlucaGen is a known history of latex anaphylaxis. This alert is specifically noted for the GlucaGen product line and should be considered during patient history assessment. Glucagon is supplied in two distinct presentations to facilitate different routes of delivery. The first is a lyophilized powder form, which provides a concentration of $1\,mg/ml$ following reconstitution using the provided $1\,ml$ vial and diluent syringe. The second presentation is the Baqsimi nasal injector, which contains $3\,mg$ of glucagon in powder form designed for intranasal ($IN$) delivery.

Dosage Protocols and Route-Specific Guidance

For the intranasal route using the Baqsimi injector, the protocol favors this method for all patients who are aged $4\,\text{years}$ or older, utilizing a single dose of $3\,mg$. For the intramuscular ($IM$) route, the dosage is strictly determined by the patient's weight. For individuals weighing less than $25\,kg$, the mandated dose is $0.5\,mg$, which corresponds to a volume of $0.5\,ml$. For patients weighing $25\,kg$ or more, the dose is increased to $1\,mg$, which constitutes the full $1\,ml$ content of the reconstituted vial. Paramedics are authorized to repeat a dose once after an interval of $15\,\text{minutes}$ if the initial clinical indications for intervention are still present.

Specialized Clinical Considerations and Administration Techniques

If a patient has already received a dose of glucagon, such as intramuscular glucagon or intranasal Baqsimi, from a third party or first responder prior to the arrival of the paramedics, the protocol requires a fresh glucose measurement. If the criteria for administration remain met, a repeat dose should be administered precisely $15\,\text{minutes}$ after the first dose was given. In the event of supply chain shortages affecting the availability of intramuscular glucagon, the Baqsimi intranasal device may be used as a substitute for patients aged $4\,\text{years}$ or older, with a single $3\,mg$ dose delivered intranasally. When using the Baqsimi device, the technique involves inserting the stem into one nostril and depressing the piston fully. The delivery is only considered successful once the piston has breached the second level of pressure resistance. Common side effects associated with glucagon administration include nausea and vomiting.

Pharmacokinetics and Pharmacodynamics of Glucagon

Glucagon is classified as a hyperglycemic hormone. When administered via the intramuscular route, the drug exhibits a high bioavailability of between $80\,\%$ and $90\,\%$. The onset of action for the medication typically occurs within a range of $5\, \text{ to } 15\,\text{minutes}$. The half-life of glucagon, specifically for the intramuscular route, is documented between $30\, \text{ to } 45\,\text{minutes}$. The maximum duration of its therapeutic effect lasts from $60\, \text{ to } 90\,\text{minutes}$. The metabolism of the hormone is conducted through three primary systems: the liver (hepatic), the blood plasma (plasmatic), and the kidneys (renal). The specific mechanism of elimination remains characterized as unknown.